BC Extra | Aug 5, 2019
Clinical News

Big gain for Allakos as first-in-class GI program heads toward pivotal phase

Allakos' management team has plenty of experience in M&A, and a new Phase II readout in eosinophilic GI disorders could provoke interest in the company as a Phase III-ready bolt-on acquisition target. Allakos Inc. (NASDAQ:ALLK)...
BioCentury | May 20, 2019
Emerging Company Profile

Reneo: Small molecules for rare mitochondrial diseases

With a $50 million series A led by NEA and a management team guided by veterans of Shire takeout Lumena, Reneo believes its small molecule could carve out a niche in the rare genetic mitochondrial...
BC Week In Review | Nov 9, 2018
Company News

Mirum launches with liver disease candidates from Shire

Mirum Pharmaceuticals Inc. (San Francisco, Calif.) launched with a $120 million series A round and a license from Shire plc (LSE:SHP; NASDAQ:SHPG) to a pair of candidates to treat liver diseases. The start-up intends to...
BC Extra | Nov 7, 2018
Financial News

Mirum launches with liver disease candidates from Shire

Mirum Pharmaceuticals Inc. (San Francisco, Calif.) launched with a $120 million series A round and a license from Shire plc (LSE:SHP; NASDAQ:SHPG) to a pair of candidates to treat liver diseases. The start-up intends to...
BioCentury | Jul 21, 2017
Finance

Itching to invest

A growing strategic interest in pruritus underlies two series C rounds with multiple new investors that were announced the week of July 17. For Trevi Therapeutics Inc. , the $50.5 million round announced July 20 is...
BioCentury | Nov 16, 2015
Finance

Clinical catalyst

After in-licensing an antifungal for $1.5 million in January, Amplyx Pharmaceuticals Inc. has used the asset to attract its first venture money in over five years and recruit a new management team focused on product...
BC Extra | Nov 12, 2015
Financial News

Amplyx raises $40.5M series B

Amplyx Pharmaceuticals Inc. raised $40.5 million in a series B round led by RiverVest Venture Partners. Other investors included New Enterprise Associates, BioMed Ventures and undisclosed individuals. Next year, the company plans to start Phase...
BC Week In Review | Apr 13, 2015
Clinical News

SHP625: Phase II data

Top-line data from the double-blind, U.K. Phase II IMAGO trial in 20 patients ages 1-18 with Alagille syndrome showed that once-daily oral SHP625 missed the primary endpoint of reducing fasting serum bile acid levels from...
BC Extra | Apr 10, 2015
Top Story

Priority Review erases Shire's losses on trial miss

Shire plc (LSE:SHP; NASDAQ:SHPG) turned early losses on clinical data into gains on Thursday, picking up $7.24 to $254.32 on NASDAQ after FDA accepted for filing and granted Priority Review to an NDA for lifitegrast...
BC Week In Review | Jan 19, 2015
Financial News

New Enterprise Associates financial update

New Enterprise Associates , Baltimore, Md.   Business: Finance   Date announced: 2015-01-13   Note: New Enterprise Associates proposed in a regulatory filing a $2.5 billion target for New Enterprise Associates 15, a new venture fund....
Items per page:
1 - 10 of 36
BC Extra | Aug 5, 2019
Clinical News

Big gain for Allakos as first-in-class GI program heads toward pivotal phase

Allakos' management team has plenty of experience in M&A, and a new Phase II readout in eosinophilic GI disorders could provoke interest in the company as a Phase III-ready bolt-on acquisition target. Allakos Inc. (NASDAQ:ALLK)...
BioCentury | May 20, 2019
Emerging Company Profile

Reneo: Small molecules for rare mitochondrial diseases

With a $50 million series A led by NEA and a management team guided by veterans of Shire takeout Lumena, Reneo believes its small molecule could carve out a niche in the rare genetic mitochondrial...
BC Week In Review | Nov 9, 2018
Company News

Mirum launches with liver disease candidates from Shire

Mirum Pharmaceuticals Inc. (San Francisco, Calif.) launched with a $120 million series A round and a license from Shire plc (LSE:SHP; NASDAQ:SHPG) to a pair of candidates to treat liver diseases. The start-up intends to...
BC Extra | Nov 7, 2018
Financial News

Mirum launches with liver disease candidates from Shire

Mirum Pharmaceuticals Inc. (San Francisco, Calif.) launched with a $120 million series A round and a license from Shire plc (LSE:SHP; NASDAQ:SHPG) to a pair of candidates to treat liver diseases. The start-up intends to...
BioCentury | Jul 21, 2017
Finance

Itching to invest

A growing strategic interest in pruritus underlies two series C rounds with multiple new investors that were announced the week of July 17. For Trevi Therapeutics Inc. , the $50.5 million round announced July 20 is...
BioCentury | Nov 16, 2015
Finance

Clinical catalyst

After in-licensing an antifungal for $1.5 million in January, Amplyx Pharmaceuticals Inc. has used the asset to attract its first venture money in over five years and recruit a new management team focused on product...
BC Extra | Nov 12, 2015
Financial News

Amplyx raises $40.5M series B

Amplyx Pharmaceuticals Inc. raised $40.5 million in a series B round led by RiverVest Venture Partners. Other investors included New Enterprise Associates, BioMed Ventures and undisclosed individuals. Next year, the company plans to start Phase...
BC Week In Review | Apr 13, 2015
Clinical News

SHP625: Phase II data

Top-line data from the double-blind, U.K. Phase II IMAGO trial in 20 patients ages 1-18 with Alagille syndrome showed that once-daily oral SHP625 missed the primary endpoint of reducing fasting serum bile acid levels from...
BC Extra | Apr 10, 2015
Top Story

Priority Review erases Shire's losses on trial miss

Shire plc (LSE:SHP; NASDAQ:SHPG) turned early losses on clinical data into gains on Thursday, picking up $7.24 to $254.32 on NASDAQ after FDA accepted for filing and granted Priority Review to an NDA for lifitegrast...
BC Week In Review | Jan 19, 2015
Financial News

New Enterprise Associates financial update

New Enterprise Associates , Baltimore, Md.   Business: Finance   Date announced: 2015-01-13   Note: New Enterprise Associates proposed in a regulatory filing a $2.5 billion target for New Enterprise Associates 15, a new venture fund....
Items per page:
1 - 10 of 36